Utilizing PK and PD Biomarkers to Guide the First-in-Human Starting Dose Selection of MTBT1466A: A Novel Humanized Monoclonal Anti-TGFβ3 Antibody for the Treatment of Fibrotic Diseases.
暂无分享，去创建一个
Y. Wu | A. Kamath | A. M. Ovacik | S. Sukumaran | W. Halpern | Victor Yip | T. Sun | J. Arron | Rajbharan Yadav | Jeff Lutman | Lin Pan | S. Glickstein | E. Stefanich | M. Neighbors | Lyrialle W. Han | Ben-Quan Shen | X. Sheng | R. Kunder | Mayur S. Mitra | A. Setiadi | Chang Liu